-

08:10:29 AM

Latest KRYS Stock Market News

KRYS - Krystal Biotech Inc

09/15/21 8:00 AM

Nasdaq : KRYS

management

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe. Mr. Goux has more than 20 years of global biotechnology

RHEA-AI

very positive

09/09/21 8:00 AM

Nasdaq : KRYS

conferences

Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS),

RHEA-AI

neutral

09/07/21 4:31 PM

Nasdaq : KRYS

conferences

Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The

RHEA-AI

neutral

08/09/21 8:00 AM

Nasdaq : KRYS

earnings

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21 Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21 Our wholly-owned subsidiary Jeune Aesthetics, Inc. initiated dosing in the efficacy

RHEA-AI

neutral

07/01/21 4:15 PM

Nasdaq : KRYS

clinical trial

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the

RHEA-AI

neutral

06/03/21 8:00 AM

Nasdaq : KRYS

conferences

Krystal Biotech to Participate in Upcoming Investor Conferences

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman Sachs 42nd Annual

RHEA-AI

neutral

05/10/21 8:00 AM

Nasdaq : KRYS

earnings

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

Krystal Biotech Inc., (“Krystal”) (NASDAQ:

RHEA-AI

neutral

05/03/21 8:00 AM

Nasdaq : KRYS

management

Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience,

RHEA-AI

very positive

04/27/21 4:35 PM

Nasdaq : KRYS

Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the

RHEA-AI

neutral

04/26/21 4:05 PM

Nasdaq : KRYS

Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic

RHEA-AI

neutral